Search results
Results from the WOW.Com Content Network
Bristol Myers Squibb and Karuna announced their merger agreement on Friday. The transaction, which amounts to $330 per share in cash, offers a premium of 53% over Karuna's stock on Thursday.
Xanomeline was licensed to Karuna Therapeutics in 2012 and KarXT was subsequently created as a dual drug formulation by adding trospium. Trospium is a non-brain-penetrant and non-selective muscarinic receptor blocker that may ameliorate the peripheral side effects of xanomeline.
(Reuters) -Bristol Myers Squibb on Friday agreed to buy Karuna Therapeutics for $14 billion, gaining a promising new type of antipsychotic medicine to help power growth as patents on its older ...
The acquisition included Karuna's lead asset, KarXT, an investigational muscarinic antipsychotic combination of Xanomeline and Trospium. [86] In November 2023, the FDA accepted Karuna Therapeutics' NDA for KarXT, for the treatment of schizophrenia in adults. [87] The acquisition of Karuna Therapeutics was completed in March 2024. [88]
The promising drug combination was discovered and tested by Karuna Therapeutics, which Bristol Myers Squibb acquired in March. Bristol Myers Squibb will sell the drug combination under the brand ...
She is the founder and CEO [1] of Seaport Therapeutics, [2] co-founder of Karuna Therapeutics, [3] and Founding CEO of PureTech Health. [4] She sits on the board of BIO [5] and is a co-founder and host of Biotech Hangout. [6] She was named one of the most influential people in Biopharma in 2023. [7] MIT Technology Review TR35 top innovators .
Bristol Myers Squibb said on Saturday data from late-stage studies of its experimental schizophrenia drug showed it helped reduce symptoms of the disorder without the common side effect of weight ...
Xanomeline is an agonist that primarily targets the muscarinic acetylcholine receptor family of five muscarinic receptor subtypes, which are designated M 1-M 5. [2] While it binds with near identical affinity to all five of the muscarinic receptor subtypes as measured by displacement of a muscarinic radioligand, the preponderance of evidence suggests that xanomeline acts preferentially in the ...